Skip to main content

Syndax Pharmaceuticals, Inc. (SNDX) Stock Analysis

Oversold Bounce setup

SellModerate Confidence

Healthcare · Biotechnology

Sell if holding. Engine safety override at $19.93: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 7.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 27%; Below-average business quality.

Syndax Pharmaceuticals is a commercial-stage oncology company with two FDA-approved products: Revuforj (revumenib, for R/R acute leukemia with KMT2A translocation or NPM1m AML, approved Nov 2024 and Oct 2025) and Niktimvo (axatilimab, for cGVHD after 2+ prior lines, approved Aug... Read more

$19.93+73.6% A.UpsideScore 4.9/10#93 of 158 Biotechnology
Stop $18.78Target $34.51(analyst − 13%)A.R:R 7.0:1
Analyst target$39.67+99.0%12 analysts
$34.51our TP
$19.93price
$39.67mean
$57

Sell if holding. Engine safety override at $19.93: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 7.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 27%; Below-average business quality. Chart setup: Oversold RSI 23, near Bollinger lower, volume surge. Score 4.9/10, moderate confidence.

Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.60, earnings proximity no date, semi cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Val7.1Qual2.6Grw5.0Mom4.1Sent7.8Ins3.8Peer3.6Tech7.6Risk1.94.9OVERALL

Thesis

Rewards
Recent Analyst detected in news
Risks
Concentration risk — Product: Revuforj
Concentration risk — Supplier: Incyte
Quality below floor (2.6 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)-85.5
Mkt Cap$1.9B
EV/EBITDA-8.4
Profit Mgn-112.0%
ROE-189.5%
Rev Growth223.6%
Beta—
DividendNone
Rating analysts20

Quality Signals

Piotroski F3/9

Options Flow

P/C0.55bullish
IV86%elevated
Max Pain$15-24.7% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHProductRevuforj
    10-K Item 1A: 'Our business currently depends heavily on our ability to successfully commercialize Revuforj in the United States'
  • HIGHSupplierIncyte
    10-K Item 1A: 'We are dependent upon our collaboration with Incyte to further develop and commercialize axatilimab'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

Volatile — 5.3% daily ATR makes tight stops impractical. Position-size conservatively.static

Days To Cover
0.0
Volatility
0.0
Implied Vol
0.0
Debt Equity
0.0
Short Interest
0.8
Max Pain Risk
3.0
Put Call
9.7
High short interest justified: 27%High IV: 86%Above max pain $15Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static

Roa
0.0
Operating Margin
0.0
Fcf Quality
0.0
Piotroski F
3.3
Moat
5.0
Current Ratio
7.5
Cash-burning: FCF -87% of revenueNo competitive moatWeak Piotroski F-Score: 3/9Quality concerns

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
0.0
Value Rank
5.3
Growth Rank
9.2
Industry growth leader
GatesMomentum 4.1<4.5A.R:R 7.0 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS BOOST ANALYST 0.60EARNINGS PROXIMITY NO DATESEMI CYCLE PEAK CLEAROversold BounceSuitability: Aggressive
RSI
23 · Oversold
↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $19.36Resistance $25.53

Price Targets

$19
$35
A.Upside+73.2%
A.R:R7.0:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (2.6 < 4.0)
! Momentum score 4.1/10 — below 4.5 minimum

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-04-30 (nulld)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is SNDX stock a buy right now?

Sell if holding. Engine safety override at $19.93: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 7.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 27%; Below-average business quality. Chart setup: Oversold RSI 23, near Bollinger lower, volume surge. Prior stop was $18.78. Score 4.9/10, moderate confidence.

What is the SNDX stock price target?

Take-profit target: $34.51 (+73.6% upside). Prior stop was $18.78. Stop-loss: $18.78.

What are the risks of investing in SNDX?

Concentration risk — Product: Revuforj; Concentration risk — Supplier: Incyte; Quality below floor (2.6 < 4.0).

Is SNDX overvalued or undervalued?

Syndax Pharmaceuticals, Inc. trades at a P/E of N/A (forward -85.5). TrendMatrix value score: 7.1/10. Verdict: Sell.

What do analysts say about SNDX?

20 analysts cover SNDX with a consensus score of 4.3/5. Average price target: $40.

What does Syndax Pharmaceuticals, Inc. do?Syndax Pharmaceuticals is a commercial-stage oncology company with two FDA-approved products: Revuforj (revumenib, for...

Syndax Pharmaceuticals is a commercial-stage oncology company with two FDA-approved products: Revuforj (revumenib, for R/R acute leukemia with KMT2A translocation or NPM1m AML, approved Nov 2024 and Oct 2025) and Niktimvo (axatilimab, for cGVHD after 2+ prior lines, approved Aug 2024 in partnership with Incyte).

Related stocks: NVAX (Novavax, Inc.) · HRMY (Harmony Biosciences Holdings, I) · AUPH (Aurinia Pharmaceuticals Inc) · CPRX (Catalyst Pharmaceuticals, Inc.) · PHAR (Pharming Group N.V.)